A Bioequivalence Study of a 68 mg Etonogestrel Implant in Healthy, Pre-Menopausal, Nonpregnant Female Subjects

The primary objective of this study is to evaluate the **bioequivalence** of an Etonogestrel 68 mg implant in healthy pre-menopausal, nonpregnant female subjects. Bioequivalence studies are crucial in determining whether a generic product releases its active ingredient into the bloodstream at the same rate and extent as the original branded product. This is clinically relevant as it ensures that the generic product will have the same therapeutic effect and safety profile as the branded version, providing a cost-effective alternative without compromising efficacy or safety.

The clinical trial involves a study population consisting exclusively of **female** participants, with an age range categorized as **3**, which typically corresponds to a specific age group as defined in clinical research. The trial does not focus on any specific **medical condition**, indicating that participants are generally healthy. The sponsor has not provided information regarding the total number of participants. The trial population was selected with consideration for vulnerable populations, although specific criteria for inclusion or exclusion have not been disclosed. Lifestyle factors such as diet, physical activity, or habits have not been specified in the available data. The absence of detailed participant information suggests that the sponsor has chosen not to disclose certain aspects of the trial population.

The clinical trial is designed to evaluate the **bioequivalence** of an Etonogestrel 68 mg implant in healthy pre-menopausal, nonpregnant female subjects. This study is a Phase 2 trial, which is categorized as a controlled trial. The trial is expected to commence recruitment on June 5, 2023, and is estimated to conclude by December 28, 2023. The trial does not involve any specific medical condition, as it targets healthy individuals.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. During this visit, eligibility criteria will be assessed to ensure that participants meet the necessary requirements for inclusion in the study. Following successful screening, participants will be randomized into the study groups. The trial will include several follow-up visits, which are scheduled to monitor the participants' response to the implant and to collect necessary data for the study's objectives. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the bioequivalence of the implant.

The expected length of participant involvement in the trial is approximately six months, aligning with the overall trial duration. Participants may be subject to early termination from the study if they experience adverse events that compromise their safety, if they withdraw consent, or if they fail to comply with the study protocol. The trial is conducted under strict adherence to ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to begin recruitment on June 5, 2023, with an estimated end date of December 28, 2023. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous clinical trial standards to ensure the reliability and validity of the efficacy outcomes.